The transaction adds laparoscopic vessel sealing, dividing, and dissecting devices to the Hologic portfolio and also will allow the company to expand the use of Bolder's devices to specialists in obstetrics/gynecology.
Bolder Surgical is expected to generate approximately $10 million of product revenue this calendar year. Hologic said the acquisition is expected to be slightly dilutive to Hologic's earnings per share in fiscal 2022, roughly break-even in fiscal 2023, and accretive thereafter.
The acquisition is expected to close by the end of the 2021 calendar year.
Copyright © 2021 AuntMinnie.com